Cargando…

CDKN3 mRNA as a Biomarker for Survival and Therapeutic Target in Cervical Cancer

The cyclin-dependent kinase inhibitor 3 (CDKN3) gene, involved in mitosis, is upregulated in cervical cancer (CC). We investigated CDKN3 mRNA as a survival biomarker and potential therapeutic target for CC. CDKN3 mRNA was measured in 134 CC and 25 controls by quantitative PCR. A 5-year survival stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Barrón, Eira Valeria, Roman-Bassaure, Edgar, Sánchez-Sandoval, Ana Laura, Espinosa, Ana María, Guardado-Estrada, Mariano, Medina, Ingrid, Juárez, Eligia, Alfaro, Ana, Bermúdez, Miriam, Zamora, Rubén, García-Ruiz, Carlos, Gomora, Juan Carlos, Kofman, Susana, Pérez-Armendariz, E. Martha, Berumen, Jaime
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570808/
https://www.ncbi.nlm.nih.gov/pubmed/26372210
http://dx.doi.org/10.1371/journal.pone.0137397
_version_ 1782390269174349824
author Barrón, Eira Valeria
Roman-Bassaure, Edgar
Sánchez-Sandoval, Ana Laura
Espinosa, Ana María
Guardado-Estrada, Mariano
Medina, Ingrid
Juárez, Eligia
Alfaro, Ana
Bermúdez, Miriam
Zamora, Rubén
García-Ruiz, Carlos
Gomora, Juan Carlos
Kofman, Susana
Pérez-Armendariz, E. Martha
Berumen, Jaime
author_facet Barrón, Eira Valeria
Roman-Bassaure, Edgar
Sánchez-Sandoval, Ana Laura
Espinosa, Ana María
Guardado-Estrada, Mariano
Medina, Ingrid
Juárez, Eligia
Alfaro, Ana
Bermúdez, Miriam
Zamora, Rubén
García-Ruiz, Carlos
Gomora, Juan Carlos
Kofman, Susana
Pérez-Armendariz, E. Martha
Berumen, Jaime
author_sort Barrón, Eira Valeria
collection PubMed
description The cyclin-dependent kinase inhibitor 3 (CDKN3) gene, involved in mitosis, is upregulated in cervical cancer (CC). We investigated CDKN3 mRNA as a survival biomarker and potential therapeutic target for CC. CDKN3 mRNA was measured in 134 CC and 25 controls by quantitative PCR. A 5-year survival study was conducted in 121 of these CC patients. Furthermore, CDKN3-specific siRNAs were used to investigate whether CDKN3 is involved in proliferation, migration, and invasion in CC-derived cell lines (SiHa, CaSki, HeLa). CDKN3 mRNA was on average 6.4-fold higher in tumors than in controls (p = 8 x 10(−6), Mann-Whitney). A total of 68.2% of CC patients over expressing CDKN3 gene (fold change ≥ 17) died within two years of diagnosis, independent of the clinical stage and HPV type (Hazard Ratio = 5.0, 95% CI: 2.5–10, p = 3.3 x 10(−6), Cox proportional-hazards regression). In contrast, only 19.2% of the patients with lower CDKN3 expression died in the same period. In vitro inactivation of CDKN3 decreased cell proliferation on average 67%, although it had no effect on cell migration and invasion. CDKN3 mRNA may be a good survival biomarker and potential therapeutic target in CC.
format Online
Article
Text
id pubmed-4570808
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-45708082015-09-18 CDKN3 mRNA as a Biomarker for Survival and Therapeutic Target in Cervical Cancer Barrón, Eira Valeria Roman-Bassaure, Edgar Sánchez-Sandoval, Ana Laura Espinosa, Ana María Guardado-Estrada, Mariano Medina, Ingrid Juárez, Eligia Alfaro, Ana Bermúdez, Miriam Zamora, Rubén García-Ruiz, Carlos Gomora, Juan Carlos Kofman, Susana Pérez-Armendariz, E. Martha Berumen, Jaime PLoS One Research Article The cyclin-dependent kinase inhibitor 3 (CDKN3) gene, involved in mitosis, is upregulated in cervical cancer (CC). We investigated CDKN3 mRNA as a survival biomarker and potential therapeutic target for CC. CDKN3 mRNA was measured in 134 CC and 25 controls by quantitative PCR. A 5-year survival study was conducted in 121 of these CC patients. Furthermore, CDKN3-specific siRNAs were used to investigate whether CDKN3 is involved in proliferation, migration, and invasion in CC-derived cell lines (SiHa, CaSki, HeLa). CDKN3 mRNA was on average 6.4-fold higher in tumors than in controls (p = 8 x 10(−6), Mann-Whitney). A total of 68.2% of CC patients over expressing CDKN3 gene (fold change ≥ 17) died within two years of diagnosis, independent of the clinical stage and HPV type (Hazard Ratio = 5.0, 95% CI: 2.5–10, p = 3.3 x 10(−6), Cox proportional-hazards regression). In contrast, only 19.2% of the patients with lower CDKN3 expression died in the same period. In vitro inactivation of CDKN3 decreased cell proliferation on average 67%, although it had no effect on cell migration and invasion. CDKN3 mRNA may be a good survival biomarker and potential therapeutic target in CC. Public Library of Science 2015-09-15 /pmc/articles/PMC4570808/ /pubmed/26372210 http://dx.doi.org/10.1371/journal.pone.0137397 Text en © 2015 Barrón et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Barrón, Eira Valeria
Roman-Bassaure, Edgar
Sánchez-Sandoval, Ana Laura
Espinosa, Ana María
Guardado-Estrada, Mariano
Medina, Ingrid
Juárez, Eligia
Alfaro, Ana
Bermúdez, Miriam
Zamora, Rubén
García-Ruiz, Carlos
Gomora, Juan Carlos
Kofman, Susana
Pérez-Armendariz, E. Martha
Berumen, Jaime
CDKN3 mRNA as a Biomarker for Survival and Therapeutic Target in Cervical Cancer
title CDKN3 mRNA as a Biomarker for Survival and Therapeutic Target in Cervical Cancer
title_full CDKN3 mRNA as a Biomarker for Survival and Therapeutic Target in Cervical Cancer
title_fullStr CDKN3 mRNA as a Biomarker for Survival and Therapeutic Target in Cervical Cancer
title_full_unstemmed CDKN3 mRNA as a Biomarker for Survival and Therapeutic Target in Cervical Cancer
title_short CDKN3 mRNA as a Biomarker for Survival and Therapeutic Target in Cervical Cancer
title_sort cdkn3 mrna as a biomarker for survival and therapeutic target in cervical cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570808/
https://www.ncbi.nlm.nih.gov/pubmed/26372210
http://dx.doi.org/10.1371/journal.pone.0137397
work_keys_str_mv AT barroneiravaleria cdkn3mrnaasabiomarkerforsurvivalandtherapeutictargetincervicalcancer
AT romanbassaureedgar cdkn3mrnaasabiomarkerforsurvivalandtherapeutictargetincervicalcancer
AT sanchezsandovalanalaura cdkn3mrnaasabiomarkerforsurvivalandtherapeutictargetincervicalcancer
AT espinosaanamaria cdkn3mrnaasabiomarkerforsurvivalandtherapeutictargetincervicalcancer
AT guardadoestradamariano cdkn3mrnaasabiomarkerforsurvivalandtherapeutictargetincervicalcancer
AT medinaingrid cdkn3mrnaasabiomarkerforsurvivalandtherapeutictargetincervicalcancer
AT juarezeligia cdkn3mrnaasabiomarkerforsurvivalandtherapeutictargetincervicalcancer
AT alfaroana cdkn3mrnaasabiomarkerforsurvivalandtherapeutictargetincervicalcancer
AT bermudezmiriam cdkn3mrnaasabiomarkerforsurvivalandtherapeutictargetincervicalcancer
AT zamoraruben cdkn3mrnaasabiomarkerforsurvivalandtherapeutictargetincervicalcancer
AT garciaruizcarlos cdkn3mrnaasabiomarkerforsurvivalandtherapeutictargetincervicalcancer
AT gomorajuancarlos cdkn3mrnaasabiomarkerforsurvivalandtherapeutictargetincervicalcancer
AT kofmansusana cdkn3mrnaasabiomarkerforsurvivalandtherapeutictargetincervicalcancer
AT perezarmendarizemartha cdkn3mrnaasabiomarkerforsurvivalandtherapeutictargetincervicalcancer
AT berumenjaime cdkn3mrnaasabiomarkerforsurvivalandtherapeutictargetincervicalcancer